FEMASYS INC

FEMYNASDAQ

🏆 #4711 by market capEarnings Aug 12US Equity

$2.33▼ $0.02 (−1.06%)

Live

1h▼ 1.9%

24h▼ 1.1%

7d▼ 24.1%

14d▼ 18.7%

30d▼ 34.6%

1y▼ 84.1%

🏦Market Cap

$7M

Small Cap

📈Revenue Growth (YoY)

+40.8%

High Growth

📊Gross Margin

53.1%

Healthy

💵FCF Margin

-783.4%

Thin

⚖️P/S Ratio

3.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $2.30 – $2.33
52-Week Range: $2.20 – $22.20
Volume: $2.33B
Avg Volume: $1.99B
Shares Outstanding: 3.0M
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $424,889
P/E Ratio: -0.4
P/S Ratio: 3.0x
EPS (TTM): $-3.72
Dividend Yield: 0.00%

Why Investors Own FEMY

✓High-growth profile — revenue up -8.6% YoY with expanding US Equity exposure.
✓Healthy economics — 72% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▼ −5.8% YoY

Gross Margin (TTM)

72.3%▲ +1.6% YoY

Operating Income (TTM)

$298,131▼ −5.8% YoY

Free Cash Flow (TTM)

$385,277▼ −5.8% YoY

About FEMASYS INC

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

🦦